Baseline levels of lactate dehydrogenase are significantly associated with progression-free survival outcomes in patients with BRAF V600–mutated metastatic melanoma.
A study using multigene panel testing identified several pathogenic variants associated with an increased risk of triple-negative breast cancer.
Targeted delivery of nanoparticles may reduce systemic and CNS toxicity in spinal cord tumors.
A study shows that receipt of radioactive iodine after reoperation may not be associated with improved outcomes.
A meta-analysis identified several factors that are correlated with locoregional recurrence in patients with nonmetastatic muscle-invasive bladder cancer.
Peripheral T-Cell Lymphomas: Incorporating New Developments in Diagnostics, Prognostication, and Treatment Into Clinical Practice—PART 2: ENKTL, EATL, Indolent T-Cell LDP of the GI Tract, ATLL, and Hepatosplenic T-Cell Lymphoma
In Part 2 of this two-part series, this review covers extranodal natural killer/T-cell lymphoma, enteropathy-associated T-cell lymphoma, indolent T-cell lymphoproliferative disorder of the gastrointestinal tract, adult T-cell leukemia/lymphoma, and hepatosplenic T-cell lymphoma.
The regimen consisting of carboplatin and paclitaxel represents the backbone of ovarian cancer treatment. Here, we reflect on our experience administering the carboplatin/paclitaxel regimen to scores of ovarian cancer patients over the past decade and a half.
This article will present feasible weight loss interventions, and will discuss practical implications of ongoing chemotherapy and endocrine therapy with regard to weight gain, and the impact of obesity on therapy-related conditions during breast cancer survivorship.
Balancing the goal of obtaining a durable remission and that of avoiding a negative impact on quality of life argues against the routine use of chemotherapy in follicular lymphoma.
It is clear that chemoimmunotherapy has redefined the history of follicular lymphoma, producing survival rates measured in decades.